WASHINGTON — The United States is set to roll out a powerful new weapon in the long fight against sexually transmitted infections: a decades-old antibiotic repurposed as a preventative pill.
Several issues are behind the rise: fewer people are using condoms since the advent of PrEP — daily pills that significantly reduce the chances of contracting human immunodeficiency virus (HIV).
And people who are on PrEP are recommended to undergo screening every three months, likely increasing the identification of infections.
Then there is the basic epidemiological fact that the greater the number of people infected, the more they can be further infected.
Researchers have found DoxyPEP efficacious in three of four trials.
“What we found was there was about a two-thirds reduction in sexually transmitted infection every three months,” Professor Annie Luetkemeyer, who co-led a US trial, told AFP.
The physician-scientist at the University of California, San Francisco recruited some 500 people in San Francisco and Seattle among communities of men who have sex with men and transgender women.
Efficacy was greatest for chlamydia and syphilis, both of which were reduced by about 80 per cent, while for gonorrhoea it was about 55 per cent. There were few side effects.
Broadening access to doxycycline has prompted concerns about causing antibiotic resistance, particularly in gonorrhoea, which is fast mutating.
But early research hasn’t shown cause for alarm.
Professor Connie Celum of the University of Washington, who co-led the US study, told AFP researchers tested gonorrhoea samples from breakthrough infections in the DoxyPEP group and compared them to the group who didn’t receive the pill.
Though they found the rate of resistant gonorrhoea slightly higher in the DoxyPEP group, she says the finding could simply mean the pill is less effective against already resistant strains, rather than causing that resistance.
DoxyPEP could even boost responsible antibiotic stewardship — cutting the incidence of infections, thus also cutting the need for antibiotic treatment.
If it slashed gonorrhoea cases by some 50 per cent, it could reduce the number of people requiring antibiotic treatment with the current frontline treatment drug, ceftriaxone, which doctors are eager to preserve.
Longer term study is required, on both impacts on STIs but also “bystander” bacteria such as Staphylococcus aureus, which live inside people’s noses but sometimes cause serious infections.
Mr Malik said that while he is glad he could use DoxyPEP as a last resort, he wishes more men were willing to use condoms. Since moving to America from South Asia, he gets relatively little interest on dating app Grindr when he says he’s not willing to have condomless sex.
But Stephen Abbott — a doctor at Washington’s Whitman-Walker clinic who prescribes and uses DoxyPEP — said it’s crucial to meet people where they are.
“From speaking with patients, and being part of the community that’s now on PrEP… I think the age of prevention through condoms is fading,” he told AFP.
A 42-year-old man in London who runs a cultural organisation told AFP that word had spread about DoxyPEP through the international gay party circuit and he had procured a supply on the black market and through a partner who buys in bulk in Mexico.
It had largely worked for him, though he did have one breakthrough infection of throat gonorrhoea. He said he was looking forward to the United Kingdom adopting similar guidance so that people have the right information and aren’t left to guess at the right dosage.
For Prof Luetkemeyer, DoxyPEP won’t be “the answer” to the STI epidemic, and there is considerable interest in the development of a gonorrhea vaccine.
“But I’m optimistic… I think this is an additional tool,” she said. AFP